SCHEMBL3695594

SCHEMBL3695594

CN(C(=O)c1n[nH]c2ccccc12)C1CC2CCCC(C1)N2C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ HTR3A P46098 4/20 0.44
▸ HTR3E A5X5Y0 1/20 0.44
▸ SLC22A2 O15244 1/20 0.44
▸ HTR3B O95264 1/20 0.44
▸ CHRNB2 P17787 1/20 0.44
▸ CHRNA3 P32297 1/20 0.44
▸ CHRNA4 P43681 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ HTR3D Q70Z44 1/20 0.44
▸ HTR3C Q8WXA8 1/20 0.44
▸ SLC47A1 Q96FL8 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ TP53 P04637 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6411553 0.99 DYRK1A (0.46) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL2087087 0.95 DYRK1A (0.48) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL2087552 0.79 GSK3B (0.51) DYRK1A
SCHEMBL2088254 0.79 GSK3B (0.51) DYRK1A
SCHEMBL12441936 0.79 NPC1 (0.68) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL2086948 0.79 NPC1 (0.68) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL2087490 0.79 NPC1 (0.68) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL2262277 0.78 RAB9A (0.50) RAB9ANPC1HTR3AKDM4EALDH1A1
SCHEMBL3375402 0.77 HTR3A (0.40) DYRK1ARAB9ANPC1HTR3AHTR3E
SCHEMBL9745866 0.77 HTR3A (0.62) HTR3AHTR3EHTR3BCHRNB2CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347012-A1 MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM Chase Pharmaceuticals Corporation (US) 2018-07-18 — — EP disclosed
EP-3347011-A1 MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM Chase Pharmaceuticals Corporation (US) 2018-07-18 — — EP disclosed
WO-2017147104-A1 MUSCARINIC M2-ANTAGONIST COMBINATIONS CHASE PHARMACEUTICALS CORPORATION (US) 2017-08-31 — — WO disclosed
WO-2017044714-A1 MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CHASE PHARMACEUTICALS CORPORATION (US) 2017-03-16 — — WO disclosed
WO-2017044693-A1 MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CHASE PHARMACEUTICALS CORPORATION (US) 2017-03-16 — — WO disclosed
EP-2478099-A1 METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA Chase Pharmaceuticals Corporation (US) 2012-07-25 — — EP disclosed
WO-2010054003-A2 METHYLINDAZOLE MODULATORS OF 5-HT3 RECEPTORS AUSPEX PHARMACEUTICAL, INC. (US) 2010-05-14 — — WO disclosed
WO-2007054784-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF GRANISETRON HYDROCHLORIDE ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2007-05-18 — — WO disclosed
EP-0979818-B1 BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-02-19 — — EP disclosed
EP-0882045-A1 PROCESS FOR THE PREPARATION OF GRANISETRON SMITHKLINE BEECHAM PLC (GB) 1998-12-09 — — EP disclosed
WO-1997030049-A1 PROCESS FOR THE PREPARATION OF GRANISETRON SMITHKLINE BEECHAM PLC (GB) 1997-08-21 — — WO disclosed
EP-0748321-A1 PROCESS FOR THE PREPARATION OF AN INDAZOLE-3-CARBOXAMIDE DERIVATIVE SMITHKLINE BEECHAM PLC (GB) 1996-12-18 — — EP disclosed
WO-1995023799-A1 PROCESS FOR THE PREPARATION OF AN INDAZOLE-3-CARBOXAMIDE DERIVATIVE SMITHKLINE BEECHAM PLC (GB) 1995-09-08 — — WO disclosed
Send feedback